Tuberculosis, which is transmitted through the respiratory tract, kills more than 1.6 million people and infects more than 10 million worldwide each year.
Bharat Biotech International Limited, in collaboration with Biofabri, has started a series of clinical trials in adults in the country to evaluate the safety, immunogenicity and efficacy of MTBVAC- the first vaccine against tuberculosis derived from a human source. According to a spokesperson at Bharat Biotech, this vaccine has been developed for two purposes: as a more effective and potentially longer-lasting vaccine than BCG vaccine for newborns, and to prevent TB disease in adults and adolescents, for whom there is currently no effective vaccine.
Tuberculosis, which is transmitted through the respiratory tract, kills more than 1.6 million people and infects more than 10 million worldwide each year.
You have exhausted your
monthly limit of free stories.
Read more stories for free
with an Express account.
Now subscribe at a special discount of 15% Use Code: ELECTION15
This premium article is free for now.
Register to read more free stories and access offers from partners.
Now subscribe at a special discount of 15% Use Code: ELECTION15
This content is exclusive for our subscribers.
Subscribe now to get unlimited access to The Indian Express exclusive and premium stories.
© The Indian Express Pvt Ltd
First uploaded on: 29-03-2024 at 04:05 IST
